Business
Strategic Alliance re lung cancer detection in USA
Strategic Alliance re lung cancer detection in USA.
About this update from Cizzle Biotechnology Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5257K\n Cizzle Biotechnology Holdings PLC\n 06 May 2022\n \n \n \n \n \n This announcement contains inside information for the purposes of article 7 of EU Regulation 596/2014 \n \n \n which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018 (\"UK MAR\")\n \n \n . Upon the publication of this announcement this inside information is now considered to be within the public domain.\n \n \n \n \n \n \n 6 May 2022\n \n \n Cizzle Biotechnology Holdings Plc\n \n \n \n \n \n (\"Cizzle Biotechnology\" or the \"Company\")\n \n \n \n \n \n Strategic Alliance to develop and market early lung cancer detection in USA\n \n \n \n \n \n \"Caring for Lives and Saving Lives through Early Detection\"\n \n \n \n \n \n Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce that it has signed a heads of terms to partner with CorePath Laboratories (\"CorePath\"), a full service cancer reference laboratory, to develop and offer its proprietary early-stage lung cancer test throughout the USA.\n \n Highlights\n \n \n · \n Heads of terms signed with\n \n CorePath Laboratories, USA, covering an intended strategic alliance to develop and offer the Company's CIZ1B based early-stage lung cancer test in the USA\n \n \n · \n CorePath is a Clinical Laboratory Improvement Amendments (\"CLIA\") and College of American Pathologists (\"CAP\") accredited laboratory \n \n · \n CorePath intends to develop and offer a clinical laboratory test throughout the USA using the Company's proprietary technology\n \n \n · \n Proposed 15% royalty and royalty sharing arrangements for the Company over all offering of products and services using CIZ1B via CorePath in the USA\n \n \n · \n Initial pilots planned\n \n \n Background\n \n \n Lung cancer is by far the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths. Each year, more people die of lung cancer than \n of colon, breast, and prostate cancers combined.\n \n \n The American Cancer Society's estimates for lung cancer in the United States for 2022 are:\n \n \n · \n About 236,740 new cases of lung cancer (117,910 in men and 118,830 in women) annually*\n \n \n · \n About 130,180 deaths from lung cancer (68,820 in men and 61,360 in women) every year*\n \n \n · \n Currently...